Intrabone marrow cord blood transplantation (IB-CBT) was proposed as a promising treatment modality to improve hematological recovery. However, clinical advantages of IB-CBT over conventional IV CBT have been unclear. We conducted a prospective singlecenter trial of IB-CBT to evaluate its safety and superiority in terms of hematological recovery. Fifteen adults with hematological malignancies were enrolled. A thawed and unwashed single cord blood unit was injected into the bilateral superior-posterior iliac crests under local anesthesia. Engraftments of neutrophils and platelets were achieved in 13 cases, with medians of 17 and 45 days, respectively. For the control, we extracted data from the Japanese nationwide database and compared the hematological recovery of contemporaneously transplanted 1135 CBT cases. Multivariate analysis revealed that IB-CBT enhanced platelet recovery (hazard ratio, 2.13; P = 0.007), but neutrophil recovery did not differ significantly (hazard ratio, 1.70; P = 0.19). Better donor chimerism was seen in the bone marrow of the ilium than of the sternum on day 14, suggesting that the local hematopoiesis at the injected site was established earlier than that at the remote bone marrow site. Collectively, IB-CBT was well tolerated and may enhance local engraftment, which promotes prompter platelet recovery than does IV-CBT.
INTRODUCTION
The outcomes of umbilical cord blood transplantation (CBT) are approaching those of bone marrow transplantation, [1] [2] [3] and CBT has figured prominently in transplantation using alternative stem cell sources. However, the major limitations of CBT have been its high rate of graft failure (10-20%) [3] [4] [5] [6] and delayed hematological recovery. Consequently, CBT is associated with a high risk of morbidity and mortality. The dose of hematopoietic progenitor cells in cord blood units is one log less than in bone marrow units. In addition, the seeding efficiency of injected cells in bone marrow has been shown to be low in animal models: only less than 10% of hematopoietic stem cells (HSCs) entered the bone marrow after IV injection of cord blood. 7, 8 Intrabone marrow CBT (IB-CBT) has been proposed as a treatment modality that potentially improves the seeding efficiency of HSCs. In preclinical animal models, hematopoiesis at the CB-injected site was enhanced after IB-CBT, which contributed to prompt hematological recovery. 9, 10 On the basis of these results some clinical trials have been performed and the tolerability of IB-CBT has been shown. [11] [12] [13] Because of the lack of comparative studies, however, whether IB-CBT indeed has clinical advantages in terms of hematological recovery is yet to be clarified. Also lacking are kinetic studies of hematopoiesis after IB-CBT in clinical settings.
To evaluate the safety of IB-CBT and its superiority in terms of hematological recovery, we conducted a phase I/II prospective single-center trial of IB-CBT (UMIN000006175) using 15 hematological malignancy cases. We then compared our data with those of 1135 IV-CBT cases extracted from the Japanese nationwide database of transplantation cases to evaluate its advantages. We also analyzed donor chimerism at the CB-injected site (ilium) and the remote site (sternum) serially to identify the site of hematopoiesis after IB-CBT.
SUBJECTS AND METHODS

Study design
The protocol for this study was approved by the institutional review board. The primary end points were the incidence of adverse events associated with the IB-CBT procedure, and neutrophil and platelet recovery. The prespecified secondary end points included overall survival, disease-free survival, nonrelapse mortality, GvHD and relapse. Fifteen patients with IB-CBT were enrolled. Assuming an anticipated rate of platelet recovery for patients with IB-CBT of 81% given in a previous study, 12 a sample size of 15 patients would provide over 80% power to reject the null hypothesis that the minimal desirable threshold rate of platelet recovery was 47%, at a 5% type 1 error rate using the exact binominal test. The threshold rate is a cutoff value not considered to be clinically meaningful and can be estimated as the rate for patients with CBT in the Japanese nationwide database.
Patients and cord blood units
Patients aged 20-65 years with hematological malignancies who required hematopoietic stem-cell transplantation and had no HLA-matched related or unrelated donors within a clinically useful time frame were enrolled. Patients possessing donor-specific anti-HLA antibodies were excluded. Written informed consent was obtained from all the patients in accordance with the Declaration of Helsinki.
The cord blood units were obtained from the Japan Cord Blood Bank Network. The HLA-A, -B and -DR serotypes were identified by highresolution molecular typing. The minimum requirement included a 4/6 HLA-antigen match (HLA-C was not taken into consideration) and a number of TNCs 42.0 × 10 7 per kg of the recipient body weight, which was determined before freezing.
Procedure of intrabone marrow injection
After a cord blood unit was thawed in a 37°C water bath, the cord blood was collected into a 50 ml syringe. The container was rinsed with 5 ml of saline solution, and the solution, assembled into the same syringe. To avoid cell loss, we did not remove DMSO by washing. Approximately 30 ml of the cord blood suspension was divided into four 10-ml syringes.
The first patient received shallow general anesthesia together with local anesthesia without intubation; all the subsequent patients received only local anesthesia with 1% lidocaine administered in the ward. After a bone marrow aspiration needle (15-gauge) was inserted into the posteriorsuperior iliac crest, 0.5 ml of bone marrow was aspirated to confirm the appropriate positioning of the needle. Subsequently, a cord blood aliquot of 7-8 ml was injected into the bone marrow over a period of 2 min, followed by 0.5 ml of saline. The injection procedure was repeated for the remaining three aliquots at two separate points on either side of the iliac crest.
The conditioning regimens, GvHD prophylaxis, and supportive therapies are described in the Supplementary Information.
Analysis of donor chimerism
Bone marrow aspiration was performed from the ilium, the site of cord blood injection, and from the sternum, the remote site from the injected bone, on days 14 and 28 after the IB-CBT. Donor chimerism was determined by quantitative PCR of short tandem repeats and by XY FISH for the sex-matched and -mismatched cases, respectively.
Statistical analysis
The time of neutrophil recovery was defined as the first day of 3 consecutive days after transplantation when the neutrophil count was maintained at ⩾ 0.5 × 10 9 /l. The time of platelet recovery was defined as the first day of 7 consecutive days when the platelet count was maintained at ⩾ 50 × 10 9 /l without transfusion support. First and second CR (CR1 and CR2) in acute leukemia, and CR1, CR2, and first and second PR (PR1 and PR2) in lymphoma were categorized into a low-risk group. Other disease statuses were categorized into a high-risk group. Acute and chronic GvHD were defined and graded according to the standard criteria.
14 Data obtained from the Japanese nationwide transplantation database (Transplant Registry Unified Management Program; TRUMP) 15 were used as the control. Patients who received unrelated single-unit CBT during the same time frame as our phase I/II trial (2011-2014), were aged older than 20 years, had AML, ALL or non-Hodgkin lymphoma, and lacked anti-HLA antibodies, were extracted from the database. Only the control patients who received transplants of cord blood units containing more than 2.0 × 0 7 cells/kg of total nucleated cells (TNCs) with 4/6 or 5/6 HLA compatibility were included. Patients participating in the clinical trials were excluded. Finally, 1135 patients were selected.
One-hundred fifty patients of the matched-pair arm were extracted from the control by the propensity score generated based on the age, diagnosis (AML, ALL or non-Hodgkin lymphoma), disease status (low or high risk), previous allogeneic transplant (0 or ⩾ 1), conditioning regimens (containing TBI ⩾ 8 Gy, busulfan 48 mg/kg PO or IV equivalent or other reduced-intensity regimens), 16 GvHD prophylaxis (calcineurin inhibitor alone, calcineurin inhibitor with short-term methotrexate, or calcineurin inhibitor with mycophenolate mofetil), and TNC dose.
The cumulative incidences of neutrophil and platelet recovery and of GvHD were assessed with the Gray test, with deaths from other causes as competing risk factors. 17 Multivariate analyses were performed with the Fine and Gray proportional hazards regression model to adjust for patient characteristics such as disease status, intensity of conditioning regimens, GvHD prophylaxis, TNC dose and HLA disparities. Overall survival and event-free survival were estimated using the Kaplan-Meier method. Donor chimerism was assessed using the Wilcoxon signed-rank test. All statistical tests were two-sided with a 0.05 significance level. Statistical analyses were Abbreviations: CNI = calcineurin inhibitor; IB-CBT = intrabone marrow cord blood transplantation; NHL = non-Hodgkin lymphoma; RIC = reduced-intensity conditioning; TNCs = total nucleated cells.
performed using EZR (Saitama Medical Center, Jichi Medical University, Saitama, Japan), 18 and SAS version 9.4 software (SAS Institute, Cary, NC, USA).
RESULTS
Patient characteristics
Between 2011 and 2014, 15 adult patients with hematological malignancies underwent IB-CBT at the University of Tsukuba Hospital. The patients' characteristics and cord blood units are summarized in Table 1 . The median age was 59 years (range, 32-64). The numbers of AML and related precursor neoplasms, ALL and non-Hodgkin lymphoma were 9, 4 and 2, respectively. Of those, seven were categorized as high risk. Three patients relapsed after a previous allogeneic transplantation. The Adverse events The first patient received general anesthesia together with local anesthesia without intubation. As the depth of the general anesthesia was shallow, we could observe the reaction to pain on injection, which led us decide to use only local anesthesia in the subsequent cases. Actually, the pain associated with the injection was well tolerated with local anesthesia with lidocaine. Abbreviations: CI = confidence interval; CNI = calcineurin inhibitor; HR = hazard ratio; NHL = non-Hodgkin lymphoma; RIC = reduced-intensity conditioning; TNCs = total nucleated cells.
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Adverse Events version 4.0. The hypotension was attributed to the tranquilizer (midazolam) administered just before the injection of the cord blood, and it recovered soon after fluid administration. After the data and safety monitoring committee judged that the cause of the hypotension was unlikely to be the cord blood injection, the trial was continued. No other complications were observed.
Hematological recovery One patient with ALL relapsed before hematological recovery, and another patient with ALL had graft failure. Neutrophil and platelet recovery was seen in the remaining 13 patients (87%). The median days of neutrophil (⩾0.5 × 10 9 /l) and platelet recovery (⩾50 × 10 9 /l without transfusion) after IB-CBT were 17 (range, 12-21) and 45 (range, 32-87) days, respectively. The median days of neutrophil and platelet recovery among the 13 engrafted patients were 17 and 43, respectively (Figure 1) . The difference in the conditioning regimens or the GvHD prophylaxis did not have an impact on hematological recovery in the IB-CBT arm ( Supplementary Figures  1 and 2) . Neutrophil recovery was achieved in 82% (median, 22 days) of the matched-pair arm of IV-CBT, and platelet recovery, in 58% (median, 78 days) of them on day 100. Univariate analysis revealed better neutrophil and platelet recovery in the IB-CBT arm (P = 0.035 and 0.0047, respectively). Platelet recovery equal to or over 20 × 10 9 /l without transfusion was also better in the IB-CBT arm (Supplementary Figure 3) . Multivariate analysis with IB-CBT cases and all the control cases was performed to compensate for the influence of the background factors that might affect the hematological recovery, such as IB-CBT, age, diagnosis, disease status, previous allogeneic transplant, conditioning regimen, GvHD prophylaxis, HLA compatibility, and TNC dose. The result showed that IB-CBT is an independent factor that enhances platelet recovery (hazard ratio, 2.13; 95% CI, 1.23-3.70; P = 0.007), although no statistical significance was found for the effect of IB-CBT on neutrophil recovery (hazard ratio, 1.70; 95% CI, 0.76-3.78; P = 0.19) ( Table 2 ).
GvHD and survival
The cumulative incidences of grade II acute GvHD, grade III-IV acute GvHD and chronic GvHD were 33% (5/15), 0% (0/15) and 13% (2/15), respectively (Figure 2a) , all of which did not differ statistically from those of the matched-pair arm of IV-CBT (data not shown). The nonrelapse mortality was 0% at 1 year. The estimated median overall survival and disease-free survival were 665 days and 479 days, respectively (Figure 2b) , neither of which differed significantly from the matched pair on univariate analysis (data not shown).
Donor chimerism
Better donor chimerism was observed in the ilium, which was the site of injection, than in the sternum in 10 out of the evaluable 11 cases on day 14; the other case showed comparable donor chimerism between the sites (Figure 3a) . A particularly marked difference between the sites was seen in the case that ended in graft failure. The signed-rank test revealed significantly better donor chimerism in the ilium (P = 0.006) on day 14. The difference between the injected site and the remote site had disappeared 28 days after IB-CBT (P = 1, Figure 3b) ; 10 out of the 11 cases achieved almost full donor chimerism in both sites, and in the graft failure case, the donor chimerism faded away completely.
DISCUSSION
In previous reports, the proportions of platelet recovery (⩾50 × 10 9 /l) after single-unit IV-CBT varied greatly: between 39 and 83% (median, 58%). [19] [20] [21] [22] [23] [24] The difference was mostly attributed to the diversity of the background factors, for instance, the disease status, 25 intensity of the conditioning regimen, 26 use of mycophenolate mofetil, 27 dose of TNCs 28 and HLA disparities, 19 which accordingly made it difficult to compare the outcomes.
To evaluate the influence of the infusion route on hematological recovery precisely, these factors must be equalized. Given the number of such factors, however, a randomized control study would require a huge number of cases. To solve this problem, for the control, we used 1135 samples from a Japanese nationwide database, which reflected real-world outcomes. This enormous number of samples enabled us to compensate for background factors that may influence hematological recovery and to evaluate the eventual superiority of IB-CBT on platelet recovery. This is the first prospective study to show statistical superiority of IB-CBT in terms of hematological recovery over single-unit IV-CBT used as a control.
Multivariate analysis did not show superiority for neutrophil recovery, but did for platelet recovery. This finding was consistent with those of previous IB-CBT studies, which showed favorable platelet recoveries of~80%. 12, 13, 29 Platelet production may be a better indicator of hematopoiesis when compared with granulocyte production, as was seen in some clinical studies. [30] [31] [32] Alternatively, this finding might be related to the HSC lacking CXCR4, which was recently identified in human cord blood.
33
CXCR4 is a vital bone marrow homing receptor, and HSCs without the receptor could be grafted only by using the intrabone marrow injection technique into NOD/SCID mice. 33 Moreover, this novel HSC was biased to erythromegakaryopoiesis, 34 which might explain the preeminence of platelet recovery in our cohort.
Previously, Brunstein et al. 11 reported no advantage from IB-CBT over hematopoietic recovery. They injected 20 ml of cell suspension into the bone marrow, whereas we used smaller aliquots of 7-8 ml each. It was reported that in a swine model, higher intrabone marrow pressure on infusion resulted in rapid drainage into the central venous circulation and cellular extravasation into the surrounding muscle and soft tissues. 35 In line with this notion, the smaller aliquots used in our study may have led to the better retention of injected stem cells in the bone marrow. In addition, Brunstein used double units of cord blood. Because IB-CBT may enhance hematopoiesis regardless of the TNCs contained in the unit, 12 ,29 the advantage of IB-CBT will be maximized under a lower dose of transplanted TNCs. Hence, this superiority may have been masked when double units of cord blood were used.
The proportion of the cord blood cells that were injected intravenously and reached the bone marrow was 4.4-7% in animal models, 7, 8 and most of the cells were trapped by other organs before reaching the bone marrow. 36 Meanwhile, the seeding efficiency to the bone marrow was enhanced 15-fold by the use of intrabone marrow infusion, 37, 38 and the retention of the donor cells at the site of injection was 6.2-fold greater than that by use of IV injection. 9 Although these studies emphasized the pivotal role of hematopoiesis at the injected site in animal models, other studies revealed the importance of hematopoiesis at the remote bone marrow site after IB-CBT. 37, 39 Therefore, the kinetics of hematopoiesis after IB-CBT are unclear. Since donor chimerism of the preengraftment phase was shown to have a significant impact on the subsequent hematological recovery, 40 we compared the chimerism at the injected site with that at the remote site to clarify the early kinetics. We found that the donor chimerism at the injected site predominated that at the remote site 14 days after IB-CBT. Conversely, the difference between both sites disappeared 28 days after the transplant. This finding suggested that efficient hematopoiesis was achieved early in the injected site and was followed by that at the remote site. A possible explanation for the delayed hematopoiesis at the remote site is that HSCs engrafted transiently at the injected site are mobilized and migrate thereafter to the remote site. Alternatively, HSCs that leak into the systemic circulation on intrabone marrow injection may eventually engraft at the remote site with lower efficiency. Curiously, the case in which donor chimerism at the remote site was markedly inferior to that at the injected site resulted in graft failure, suggesting that hematopoiesis at the injected site alone was not sufficient for subsequent engraftment.
A major limitation of our study is that it was a nonrandomized trial. The data from our prospective cohort were compared with registry-based data as the control. To avoid arbitrary decisions on patient selection, the enrollment criteria for the database were chosen on the basis of the criteria for the prospective study. In addition, to avoid selection bias, matched-pair and multivariate analyses were performed for adjustment of the differences in patient characteristics between the groups. The small sample size of the IB-CBT group was another limitation. Therefore, we limited the discussion to comparison of hematological recovery. It was beyond the scope of the study to compare other outcomes, such as overall survival and relapse-free survival, which are more susceptible to various factors when using small samples. Also, this small cohort did not have sufficient statistical power to detect differences in GvHD frequency.
In conclusion, IB-CBT could be performed safely and enhanced platelet recovery after transplantation. Also, analysis of donor chimerism suggested efficient hematopoiesis at the injected site early after IB-CBT. Prompt platelet recovery can lead to reduction in hemorrhagic complications and in the total burden of platelet transfusion, the latter of which can decrease the total cost of transplantation. Moreover, faster platelet recovery was shown to result in lower transplant-related mortality, 22 and actually, nonrelapse mortality was not observed within a year in our cohort. The advantage of the IB-CBT technique was the lack of need for particular equipment or additional costs as compared with other attempts to enhance hematological recovery, such as ex vivo cord blood expansion. Although most of the previous studies of intrabone marrow injection used general anesthesia, this study showed that local anesthesia was adequate to control discomfort related to the procedure, which can encourage the convenience of IB-CBT. This study will be a stepping stone for a future, larger-scale study to clarify the advantages of IB-CBT.
